Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $700.00 Consensus PT from Analysts

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been assigned an average recommendation of “Hold” from the three research firms that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $700.00.

A number of equities analysts have commented on ATRA shares. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, May 22nd. StockNews.com upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, April 5th.

Insider Activity

In other Atara Biotherapeutics news, EVP Anhco Nguyen sold 1,715 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $15.50, for a total value of $26,582.50. Following the completion of the sale, the executive vice president now directly owns 35,939 shares in the company, valued at $557,054.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Atara Biotherapeutics news, EVP Anhco Nguyen sold 1,715 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $15.50, for a total value of $26,582.50. Following the completion of the sale, the executive vice president now directly owns 35,939 shares in the company, valued at $557,054.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Pascal Touchon sold 3,260 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $15.50, for a total transaction of $50,530.00. Following the completion of the transaction, the chief executive officer now directly owns 73,165 shares of the company’s stock, valued at approximately $1,134,057.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,120 shares of company stock worth $94,860. Corporate insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Josh Arnold Investment Consultant LLC raised its holdings in shares of Atara Biotherapeutics by 17.6% during the third quarter. Josh Arnold Investment Consultant LLC now owns 200,000 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 30,000 shares during the last quarter. Vontobel Holding Ltd. acquired a new stake in Atara Biotherapeutics during the fourth quarter valued at $41,000. Redmile Group LLC grew its position in Atara Biotherapeutics by 3.8% during the third quarter. Redmile Group LLC now owns 6,280,813 shares of the biotechnology company’s stock valued at $9,296,000 after buying an additional 232,690 shares during the period. Staley Capital Advisers Inc. grew its position in Atara Biotherapeutics by 33.3% during the third quarter. Staley Capital Advisers Inc. now owns 1,000,000 shares of the biotechnology company’s stock valued at $1,480,000 after buying an additional 250,000 shares during the period. Finally, Harbor Capital Advisors Inc. grew its position in shares of Atara Biotherapeutics by 368.0% in the fourth quarter. Harbor Capital Advisors Inc. now owns 208,827 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 164,206 shares during the period. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Price Performance

Atara Biotherapeutics stock opened at $8.23 on Friday. Atara Biotherapeutics has a 1-year low of $4.96 and a 1-year high of $63.38. The firm has a market capitalization of $39.67 million, a P/E ratio of -0.15 and a beta of 0.54. The company’s 50-day moving average is $14.97 and its 200 day moving average is $16.44.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($5.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($9.25) by $3.50. The company had revenue of $27.36 million for the quarter, compared to analyst estimates of $27.00 million. Atara Biotherapeutics had a negative net margin of 671.70% and a negative return on equity of 783.31%. Research analysts anticipate that Atara Biotherapeutics will post -15.75 earnings per share for the current fiscal year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.